Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice |
| |
| Authors: | Koric L Felician O Ceccaldi M |
| |
| Affiliation: | 1. Service de neurologie et neuropsychologie, AP–HM, hôpital de la Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France;2. Inserm U751, laboratoire épilepsie et cognition, faculté de médecine, université de la Méditerranée, 13005 Marseille, France;1. APHM, hôpital Timone adultes, Timone, service de neurologie et neuropsychologie, Marseille, France;2. Aix-Marseille Université, INS UMR_S 1106, Inserm, 13005 Marseille, France;1. Hôpital neurologique Pierre Wertheimer et CMRR, CHU de Lyon, service de neurocognition et neuro-ophtalmologie, consultation mémoire, Lyon, France;2. Hôpital Pitié-Salpétrière et institut du cerveau et de la moëlle épinière-Inserm U1127, CNRS UMR7225, AP–HP université de la Sorbonne, centre national de référence des démences rares et précoces, IM2A, département de neurologie, AP–HP, Paris, France;3. Université de Rouen, CHU de Rouen, service de neurologie et centre national de référence malades Alzheimer Jeunes, laboratoire inserm UMR 1245, UFR Santé, Rouen, France;1. Laboratoire de génétique médicale et pathologies moléculaires, faculté de médecine et de pharmacie, 19, rue Tarik Ibnou Ziad, BP 9154, 20000 Casablanca, Maroc;2. Service de neurologie, CHU Ibn Rochd, 20000 Casablanca, Maroc;1. Laboratoire de génétique médicale et pathologies moléculaires, faculté de médecine et de pharmacie, 19, rue Tarik Ibnou Ziad, BP 9154, 20000 Casablanca, Maroc;2. Service de neurologie, CHU Ibn Rochd, 20000 Casablanca, Maroc;3. EGMVE, Faculté Polydisciplinaire de Taroudant, Université IBN ZOHR, Taroudanat, Maroc |
| |
| Abstract: | ![]()
INTRODUCTION: The diagnosis of Alzheimer's disease (AD) currently relies on clinical criteria that are primarily based on the presence of an amnestic syndrome of the mesial temporal lobe type. In recent years, new diagnostic tools have been developed, such as the possibility of measuring a set of proteins directly involved in the pathophysiological process of AD. A profile suggestive of AD has been defined, characterized by decreased beta-amyloid peptide, combined with increased Tau protein and phopho-Tau. STATE OF KNOWLEDGE: According to current data available in the medical literature, the potential usefulness of CSF biomarkers in the common forms of AD fulfilling usual clinical criteria remains modest. In contrast however, they could be of significant help in the diagnosis of early-onset AD, in particular in atypical forms with prominent non-memory impairment (involving vision, language or behavior). In addition, due to their close relationship with the pathological process, they bring useful prognosis information upon the aggressiveness of the disease. CONCLUSION AND PERSPECTIVE: Taken together, in the current state of knowledge, use of CSF biomarkers in clinical practice should first be recommended for the assessment of early-onset cognitive disturbances, in particular when initial symptoms are of a non-memory type. Their development, however, offers new avenues in the fields of clinical and pharmacological research. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
